Skip to main content

In order to access the website of Winterflood Securities Limited you must first read and accept the following terms:

This website is not directed at, or intended for distribution to or use by, any U.S. citizen, person, or entity that resides in or is located in the United States of America or any other jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation which would subject Winterflood to any registration or licensing requirements with such jurisdiction. Services are not available to U.S. persons except where such services are permitted under SEC rule 15a6 or other relevant exemptions from SEC Broker/Dealer registration requirements.

Research on this Website

Research on this website has been issued for the information of Professional Clients and Eligible Counterparties (as defined in the FCA handbook) of Winterflood Securities Ltd (“Winterflood”). The terminology used within the research reports is intended for professional investors. Research reports are not intended to provide the sole basis for any evaluation of an investment decision.

Each research report on this website must be read in conjunction with any disclaimer which forms part of it. Your attention is drawn to the date of issue of the information provided and of the opinions expressed therein. Any opinions are those of the Winterflood Investment Trust research team and are subject to change without notice and Winterflood is not under any obligation to update or keep current the information contained herein. The material on this website is based on information obtained from sources believed to be reliable but which have not been independently verified and are not guaranteed as being accurate.

Use of Cookies

For information on the cookies used on our websites, please refer to our Cookies Policy which can be accessed here.

Privacy

For information on how we treat your personal data, please refer to our Privacy Notice which can be accessed here.

More information can be found in our Legal Disclaimer

If you have read and accepted the terms and conditions for use of this website please click continue
01 Feb 2021

Schroder UK Public Private

Company Notes

Sale of assets for £52m

On 27 January Schroder UK Public Private Trust announced that it had agreed to sell a basket of seven assets to Rosetta Capital VI for £49m. This represented a 22% discount to the aggregate valuations as at 30 September 2020 or 19% when adjusted for foreign exchange movements. The basket includes Carrick Therapeutics, Mission Therapeutics, PsiOxus Therapeutics and Mereo BioPharma and partial holdings in Inivata, Immunocore and ReNeuron. They are unquoted, except Mereo BioPharma and ReNeuron, although the IPO of Immunocore is scheduled for February. Rosetta Capital, a UK-based life science venture capital firm, has also agreed to pay £2.9m reflecting follow-on investments made in January. The initial proceeds will therefore total £51.9m.



In addition, an earn-out clause has been agreed that would see an additional payment of up to £5m dependent on certain value thresholds on a future exit of the investment in Immunocore. After its IPO, Rosetta will be bound under the 6-month lock-up agreement as previously agreed by the fund. There is also a potential adjustment to the acquisition price in the event of significant changes in the value of the two listed companies in the basket.



The transaction is expected to close in late February or March, while the valuation will be reflected in the NAV as at 31 December 2020, which should be announced in April. A significant proportion of the proceeds will be used to pay down the outstanding debt under the credit facility, whereby the current term loan will convert to a revolving credit facility. The intention is to use the additional liquidity to support some portfolio companies with follow-on capital and make new investments.